Objective:To assess the efficacy and safety profile of anlotinib-based chemotherapy as the primary treatment modality for PSTC.Methods:This study included patients with locally advanced or metastatic PSTC who had not received any prior anti-tumor treatments between Jan. 2018 and Jul. 2023 at the Department of Breast Surgery, First Affiliated Hospital of the University of Science and Technology of China. The enrolled patients were administered anlotinib at a dose of 12 mg every 1 to 14 days for a total duration of 21 days, across 2 to 6 cycles. The chemotherapy regimen comprised paclitaxel, capecitabine, or docetaxel in combination with carboplatin or capecitabine. The assessed endpoints included the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and disease-specific survival (DSS) .Results:Fourteen patients were recruited for the study. Among them, one patient achieved a CR, seven patients attained a PR, five patients exhibited SD, and one patient presented with PD. The highest recorded ORR was 57.1%, accompanied by a DCR of 64.3%. The median PFS was 3.7 months, and the median DSS was 7.8 months. Notably, approximately 71.4% of patients experienced adverse events (AEs). The majority of AEs were manageable, with only one patient requiring a dosage adjustment, and no patients discontinued medication due to AEs.Conclusions:Anlotinib-based chemotherapy, as the primary therapeutic approach, demonstrates safety and efficacy in managing patients diagnosed with PSTC.

Objective:To assess the efficacy and safety profile of anlotinib-based chemotherapy as the primary treatment modality for PSTC.Methods:This study included patients with locally advanced or metastatic PSTC who had not received any prior anti-tumor treatments between Jan. 2018 and Jul. 2023 at the Department of Breast Surgery, First Affiliated Hospital of the University of Science and Technology of China. The enrolled patients were administered anlotinib at a dose of 12 mg every 1 to 14 days for a total duration of 21 days, across 2 to 6 cycles. The chemotherapy regimen comprised paclitaxel, capecitabine, or docetaxel in combination with carboplatin or capecitabine. The assessed endpoints included the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and disease-specific survival (DSS) .Results:Fourteen patients were recruited for the study. Among them, one patient achieved a CR, seven patients attained a PR, five patients exhibited SD, and one patient presented with PD. The highest recorded ORR was 57.1%, accompanied by a DCR of 64.3%. The median PFS was 3.7 months, and the median DSS was 7.8 months. Notably, approximately 71.4% of patients experienced adverse events (AEs). The majority of AEs were manageable, with only one patient requiring a dosage adjustment, and no patients discontinued medication due to AEs.Conclusions:Anlotinib-based chemotherapy, as the primary therapeutic approach, demonstrates safety and efficacy in managing patients diagnosed with PSTC.

Hodgkin lymphoma (HL) is a highly curable malignancy for most patients, while the treatment of relapsed and refractory HL is still a difficult and important field. A high dose of chemotherapy with autologous stem cell transplantation is treated as the preferred treatment with a high relapse incidence. The 59th American Society of Hematology Annual Meeting reported the recent progress of the treatment of relapsed and refractory HL, including the improvement of traditional high dose chemotherapy regimens, the new drugs or therapies like brentuximab vedotin, nivolumab, pembrolizumab and ibrutinib, and chimeric antigen receptor T-cell. This review focuses on these advances.